Hot Features
Premium
Level up your trading with our powerful tools and real-time insights all in one place.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - |
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| LianBio | LIAN | NASDAQ | Depository Receipt |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.319 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.319 | 0.319 |
| Trades | Shares Traded | Average Volume |
|---|---|---|
| 0 | 0 | - |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | 0.319 | USD |
LianBio Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 0 | 0.00 | - | 0 | 311.41M | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
News LianBio
| Date | Time | Source | Heading |
|---|---|---|---|
| 3/11/2024 | 06:51 | Edgar (US Regulatory) | Form 25 - Notification of the removal from listing and.. |
| 2/28/2024 | 06:00 | GlobeNewswire Inc. | LianBio Announces Voluntarily Delisting from Nasdaq |
| 2/20/2024 | 15:10 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 2/13/2024 | 06:04 | Edgar (US Regulatory) | Form 8-K - Current report |
| 2/13/2024 | 06:00 | GlobeNewswire Inc. | LianBio Announces Completion of Strategic Review |
| 1/08/2024 | 05:13 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities |
| 12/29/2023 | 06:56 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities |
| 12/26/2023 | 15:10 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of.. |
| 12/26/2023 | 15:07 | Edgar (US Regulatory) | Form 8-K - Current report |
| 12/26/2023 | 13:40 | AllPennyStocks.com | Biotech Finds Success Following Holiday Weekend |
| 12/26/2023 | 01:00 | GlobeNewswire Inc. | LianBio Enters into Agreement Assigning its Rights for.. |
| 12/20/2023 | 07:05 | Edgar (US Regulatory) | Form 8-K - Current report |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
LIAN Historical
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Year | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 5 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| LianBio is a science-driven biopharmaceutical company dedicated to developing and commercializing innovative medicines for patients with unmet medical needs, with an initial focus on in-licensing assets for Greater China and other Asian markets. It is advancing a diversified portfolio of clinically validated product candidates with the potential to drive new standards of care across cardiovascular, oncology, ophthalmology, inflammatory disease and respiratory indications. |
